Fidelity Investments reports a 2.74% Q1 loss for its Balanced Fund. See how equity picks and bond strategy shaped results.

Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis ...

The Chicago Transit Authority (CTA) has opened its new Lawrence, Argyle, Berwyn and Bryn Mawr Red Line stations. The station ...

The 2025 MLB All-Star Game is just a few short weeks away, with the baseball world set to converge on Truist Park in Atlanta for the annual exhibition of the game's best and brightest.

Pfizer Inc. has initiated a new clinical study titled A Phase 1, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and ...

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors Phase 1 dose-escalation study to ...

Nearly one year after opening its doors, the UHS Wilson Main Tower at UHS Wilson Medical Center has become a defining symbol of a new era in healthcare for the Greater Binghamton region.

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of ...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials ...

The sCAR-T platform developed by Calibr-Skaggs is designed to enhance the precision and safety of CAR-T therapies, and has demonstrated promising preliminary results in a phase 1 clinical trial ...

Eli Lilly has shared phase 1 data on amylin analog eloralintide, impressing analysts with results that point to the potential for the drug candidate to form part of a market-leading Zepbound ...

Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.